| CJH Stock | | | EUR 3.98 0.04 1.02% |
Chairman
Xuefeng Yu is Executive Chairman of the Board, Chief Executive Officer, General Manager of CanSino Biologics since 2009.
| Age | 59 |
| Tenure | 15 years |
| Phone | 400 922 2099 |
| Web | https://www.cansinotech.com |
CanSino Biologics Management Efficiency
The company has return on total asset
(ROA) of
(0.0207) % which means that it has lost $0.0207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.0111 %, meaning that it generated $0.0111 on every $100 dollars invested by stockholders. CanSino Biologics' management efficiency ratios could be used to measure how well CanSino Biologics manages its routine affairs as well as how well it operates its assets and liabilities.
CanSino Biologics has accumulated 40
M in total debt with debt to equity ratio
(D/E) of 0.13, which may suggest the company is not taking enough advantage from borrowing. CanSino Biologics has a current ratio of 2.86, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist CanSino Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, CanSino Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CanSino Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CanSino to invest in growth at high rates of return. When we think about CanSino Biologics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | CHAIRMAN Age |
| Cynthia Egan | The Hanover Insurance | 64 |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the Peoples Republic of China. CANSINO BIOLOGICS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 726 people. CanSino Biologics (CJH) is traded on Frankfurt Exchange in Germany and employs 1,946 people.
Management Performance
CanSino Biologics Leadership Team
Elected by the shareholders, the CanSino Biologics' board of directors comprises two types of representatives: CanSino Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CanSino. The board's role is to monitor CanSino Biologics' management team and ensure that shareholders' interests are well served. CanSino Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CanSino Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Zhu Tao, Chief Scientific Officer, Deputy General Manager, Executive Director | |
| Yonghui Wu, VP Marketing | |
| WingYu Leung, Non-Executive Director | |
| Jianzhong Liu, Independent Non-Executive Director | |
| FCS FCIS, Joint Sec | |
| Dongxu Qiu, Senior Vice President Deputy General Manager, Executive Director | |
| Qiang Xu, Non-Executive Director | |
| Jing Wang, Vice President - Finance and Capital Markets, Secretary of The Board | |
| Huihua Mao, Senior Vice President Deputy General Manager | |
| Zhu Xin, Non-Executive Independent Director | |
| Jin Cui, Joint Company Secretary | |
| Xuefeng Yu, Executive Chairman of the Board, Chief Executive Officer, General Manager | |
| Tao Zhu, Ex CoFounder | |
| Chunlin Xin, Director Department | |
| Shuifa Gui, Independent Non-Executive Director | |
| Xi Luo, Chief Officer | |
| Liang Lin, Non-Executive Director | |
| Shiu Wai, Non-Executive Independent Director | |
| Ming Chiu, Joint Company Secretary | |
| Dongxu MBA, Exec CoFounder | |
| Xiao Zhi, Non-Executive Independent Director | |
| ShouBai Chao, COO Director | |
| Shou Chao, Chief Operating Officer, Deputy General Manager, Executive Director | |
CanSino Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CanSino Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in CanSino Stock
CanSino Biologics financial ratios help investors to determine whether CanSino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.